BioSpace News Archive

Harbor BioMed announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND.

WuXi Vaccines, a leading global Contract Development and Manufacturing Organization, announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed’s manufacturing facility in Suzhou will be transferred to WuXi Vaccines.

Azenta, Inc. reported financial results for the fourth quarter and fiscal year ended September 30, 2022.

Instil Bio, Inc., a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, reported its third quarter 2022 financial results and provided a corporate update.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the third quarter ended September 30, 2022.

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the third quarter ended September 30, 2022.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported results for the quarter ended September 30, 2022, and highlighted recent corporate events.

Movano Inc. dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update.

Insulet Corporation, announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable.

Viracta Therapeutics, Inc., a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that the Compensation Committee of Viracta’s Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 80,000 shares of common stock.